Fulcrum Therapeutics Inc (FULC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fulcrum Therapeutics Inc (FULC) has a cash flow conversion efficiency ratio of -0.072x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.19 Million) by net assets ($198.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see FULC market cap for the company's overall valuation and market capitalisation.
Fulcrum Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Fulcrum Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Fulcrum Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fulcrum Therapeutics Inc ranked by their cash flow conversion efficiency. Explore FULC cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Falcon Oil & Gas Ltd.
V:FO
|
-0.027x |
|
Pennar Industries Limited
NSE:PENIND
|
0.099x |
|
Sinpas Gayrimenkul Yatirim Ortakligi AS
IS:SNGYO
|
-0.005x |
|
Launch Two Acquisition Corp. Class A Ordinary Shares
NASDAQ:LPBB
|
0.000x |
|
Kardemir Karabuk Demir Celik Sanayi ve Ticaret AS Class A
IS:KRDMA
|
0.031x |
|
Shandong Huapeng Glass Co Ltd
SHG:603021
|
0.035x |
|
Shinsegae Inte
KO:031430
|
-0.046x |
|
Kalekim Kimyevi Maddeler Sanayi & Ticaret AS
IS:KLKIM
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Fulcrum Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Fulcrum Therapeutics Inc from 2017 to 2024. View Fulcrum Therapeutics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $243.03 Million | $-2.22 Million | -0.009x | +97.64% |
| 2023-12-31 | $235.19 Million | $-90.97 Million | -0.387x | +20.72% |
| 2022-12-31 | $198.94 Million | $-97.05 Million | -0.488x | -31.50% |
| 2021-12-31 | $211.54 Million | $-78.48 Million | -0.371x | +34.19% |
| 2020-12-31 | $95.18 Million | $-53.66 Million | -0.564x | -24.43% |
| 2019-12-31 | $87.15 Million | $-39.48 Million | -0.453x | -52.60% |
| 2018-12-31 | $76.00 Million | $-22.56 Million | -0.297x | +98.04% |
| 2017-12-31 | $1.32 Million | $-20.07 Million | -15.185x | -- |
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalasse… Read more